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INTRODUCTION
Lymph nodes are the most common site of metastatic tumor
and sometimes constitute the first clinical manifestation of
the disease (1). One of the pathologist's task is to provide in-
formation about possible primary source for clinicians. The
metastatic tumors in the lymph node sometimes show near-
ly identical histopathologic features irrespective of the site
of origin, and identification of the primary tumor location
may be impossible on purely morphologic ground. The ana-
tomic location of a lymph node involved by metastatic tumor
provides an important indication of the primary site of ori-
gin. Especially in cervical lymph node, high cervical lymph
nodes may harbor metastatic carcinomas originating in head
and neck, whereas low cervical lymph nodes are commonly
the site of metastases from intrathoracic carcinomas, particu-
larly in the lungs, and intraabdominal tumors, and the supra-
clavicular lymph nodes are most often the site of metastases
for abdominal (gastric) cancers (2). Immunohistochemical
approaches using tissue-specific antibodies, especially against
lung and gastrointestinal tract (GIT), are helpful to locate the
primary tumor sites in work-up for metastatic tumors of cer-
vical lymph nodes. 
Thyroid transcription factor-1 (TTF-1) is a nuclear tran-
scription protein identified by Civitareale et al. (3) in 1989.
TTF-1 is a 38-kDa homeodomain-containing nuclear protein
that is a member of the Nkx2 gene family and plays a role in
transcriptional activation during embryogenesis in the thy-
roid, diencephalon, and respiratory epithelium (4-6). TTF-1
is encoded by a single locus gene on chromosome 14q13 and
regulates the expression of several genes including thyroglobu-
lin, thyroperoxidase, sodium-iodide transport protein, calci-
tonin, and major histocompatability complex class I gene in
the thyroid (7-9) and surfactant proteins A, B, and C, and
Clara cell secretory protein gene in the lung (10-13). TTF-1
expression has been demonstrated in neoplasms of the lung
and thyroid (14, 15). 
Cytokeratin 20 (CK20) is a low-molecular-weight cyto-
keratin that was originally identified by Moll et al. (16-18)
as protein IT in two-dimensional gel electrophoresis of
cytoskeletal extracts of intestinal epithelium. In normal tis-
sues, it is expressed only in the gastrointestinal epithelium,
urothelium, and Merkel cell (17, 18). 
Therefore, we speculated that TTF-1 and CK20 immuno-
histochemial expressions might be useful in distinguishing
metastatic lung and GIT carcinomas in the cervical lymph
node, respectively. 
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Utility of Thyroid Transcription Factor-1 and Cytokeratin 20 in Identifying
the Origin of Metastatic Carcinomas of Cervical Lymph Nodes
The identification of primary location of a metastatic tumor is a difficult diagnostic
problem and sometimes can be facilitated by the use of immunohistochemical
markers. Thyroid transcription factor-1 (TTF-1) is a 38-kDa nuclear homeodomain
transcription factor that is expressed specifically in lung or thyroid neoplasms.
Cytokeratin 20 (CK20) is a 46-kDa low-molecular-weight cytokeratin that shows
restricted expression in adenocarcinomas of the gastrointestinal tract (GIT) and
transitional cell carcinomas of the urinary tract. We studied the immunohistochem-
ical expression of TTF-1 and CK20 in 68 metastatic carcinomas in cervical lymph
nodes. The primary sites were the lung in 29 cases, stomach in 13, colorectum
in 3, and other sites in 23. TTF-1 expression was detected in 69.0% of metastatic
lung carcinomas and none in metastatic GIT carcinomas, whereas CK20 expres-
sion was detected in 68.8% of metastatic GIT carcinomas and none of metastat-
ic lung carcinomas. TTF-1 had a specificity of 0.95 and a sensitivity of 0.69 for
metastatic lung carcinoma, whereas CK20 had a specificity of 1.00 and a sensi-
tivity of 0.69 for metastatic GIT carcinoma. These results indicate that TTF-1 and
CK20 should be the first choice as a component of antibody panel to prove or to
exclude the lung and GIT origin, respectively, especially in patients presenting
with metastatic carcinomas of unknown primary site. 
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Materials
The study material was obtained from the files of the De-
partment of Pathology at Dong-A University Hospital. It
consisted of 68 metastatic carcinomas in the cervical lymph
nodes. The primary sites of the study specimens were the lung
in 29 cases (11 adenocarcinomas, 8 squamous cell carcinomas,
7 small cell carcinomas, and 3 undifferentiated carcinomas),
adenocarcinoma of the stomach in 13, undifferentiated or
squamous cell carcinomas of the nasopharynx in 5, infiltrat-
ing ductal carcinomas of the breast in 4, adenocarcinomas of
the colorectum in 3, squamous cell carcinomas of the esoph-
agus in 3, transitional cell carcinomas of the ureter in 2, squa-
mous cell carcinomas of the uterine cervix in 2, and in one
each for papillary and medullary carcinoma of the thyroid,
carcinoma ex pleomorphic adenoma of the submandibular
gland, adenocarcinoma of the prostate, mucinous cystadeno-
carcinoma of the ovary, hepatocellular carcinoma of the liver,
and squamous cell carcinoma of the tongue. The primary sites
of each case were verified by comparing the histologic features
between metastases and primary tumors that had been re-
sected or biopsied simultaneously, previously, or afterward.
Immunohistochemical Staining for TTF-1 and CK20
Immunohistochemical studies for TTF-1 and CK20 were
performed on formalin-fixed, paraffin-embedded, 4  m-thick
tissue sections using the avidin-biotin-peroxidase complex
method. The primary antibodies used were the 8G7G3/1 anti-
TTF-1 monoclonal antibody (1:50, Neomarker, CA, U.S.A.)
and the KS20.8 anti-CK20 monoclonal antibody (1:100,
Dako, Copenhagen, Denmark). Deparaffinization of all sec-
tions was performed through a series of xylene baths and re-
hydration was performed through graded alcohols. To enhance
the immunoreactivity, microwave antigen retrieval at 750W
for 30 min in citrate buffer (pH 6.0) was performed for TTF-
1, and the sections for CK20 immunostaining were digested
with pepsin at room temperature for 15 min. After blocking
the endogenous peroxidase activity with 5% hydrogen per-
oxidase for 10 min, the primary antibody incubation for TTF-
1 and CK20 was performed at 4℃ overnight. Detection of
the immunoreactive staining was carried out by the avidin-
biotin-peroxidase complex method using the Histostain-plus
kit (Zymed, CA, U.S.A.). The antigen-antibody reaction was
visualized using 3-amino-9-ethylcarbazole as a chromogen.
The Mayer's hematoxylin counterstain was performed. 
To exclude equivocal reactions from data, staining was con-
sidered positive if >10% of the nuclei reactivity with any in-
tensity for TTF-1 and cytoplasmic or membranous reactivity
for CK20 were seen. 
Statistical Analysis
The specificity and sensitivity of immunohistochemical
stainings were calculated by using standard statistical methods
as follows:
Specificity=true negatives/true negatives+false positives
Sensitivity=true positives/true positives+false negatives 
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Fig. 1. Metastatic adenocarcinoma from the lung. (A) Photomicrograph showing papillary adenocarcinoma (H&E, ×40). (B) Immunohis-
tochemical stain for TTF-1 shows nuclear positivity (×40). (C) High magnification of TTF-1 immunoreactivity (×400). (D) Immunohistochemi-
cal stain for CK20 shows negative reactivity (×40).
A B C DFor TTF-1 immunohistochemical study, false positives were
defined as extrapulmonary tumors with positive staining for
TTF-1 and false negatives as tumors of pulmonary origin lack-
ing detectable staining for TTF-1. For CK20 immunohisto-
chemical study, false positives were defined as extra-GIT
tumors with positive staining for CK20 and false negatives
as tumors of GIT origin lacking detectable staining for CK20.
RESULTS
TTF-1 immunoreactivity was highlighted by a fine gran-
ular to diffuse pattern of staining confined to the nuclei inde-
pendent of labeling intensity. Cytoplasmic immunostaining
was sometimes encountered as a faint and diffuse labeling,
but it was not counted as TTF-1 immunoreactivity (Fig. 1).
CK20 immunostaining showed cytoplasmic or membra-
nous reactivity. In many cases, however, the staining showed
a mosaic-like pattern of alternating positive and negative cells
(Fig. 2). 
TTF-1 expression was detected in 69.0% (20/29) in meta-
static lung carcinomas and none (0/16) in metastatic GIT
adenocarcinomas, whereas CK20 expression was detected in
68.8% (11/16) in metastatic GIT adenocarcinomas and none
(0/29) in metastatic lung carcinomas. Metastatic tumors from
other sites showed TTF-1 expression in each case of 2 thyroids
and 2 uterine cervical cancers and did not express CK20 in
all other tumors (Table 1).
The metastatic tumor from the lung showed TTF-1 im-
munoreactivity in 90.9% (10/11) of adenocarcinomas and in
85.7% (6/7) of small cell carcinomas. The metastatic tumor
from the GIT showed CK20 immunoreactivity in 100% (3/3)
of colorectal adenocarcinomas and in 61.5% (8/13) of gastric
adenocarcinomas. TTF-1 was expressed in 2 of 39 extrapul-
monary tumors and CK20 was not expressed in any of the
52 extra-GIT tumors.
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Lung 29 20 (69.0) 0 (0)
Adenocarcinoma 11 10 (90.9) 0 (0)
Small cell carcinoma 7 6 (85.7) 0 (0)
Squamous cell carcinoma 8 3 (37.5) 0 (0)
Undifferentiated carcinoma 3 1 (33.3) 0 (0)
Gastrointestinal tract 16 0 (0) 11 (68.8)
Stomach 13 0 (0) 8 (61.5)
Colorectum 3 0 (0) 3 (100)
Nasopharynx 5 0 (0) 0 (0)
Breast 4 0 (0) 0 (0)
Esophagus 3 0 (0) 0 (0)
Thyroid 2 1 (50) 0 (0)
Ureter 2 0 (0) 0 (0)
Uterine cervix 2 1 (50) 0 (0)
Submandibular gland 1 0 (0) 0 (0)
Prostate 1 0 (0) 0 (0)
Ovary 1 0 (0) 0 (0)
Liver 1 0 (0) 0 (0)
Tongue 1 0 (0) 0 (0)




Table 1. Results of TTF-1 and CK20 immunohistochemical
staining in metastatic carcinomas of cervical lymph node
Positive (%)
TTF-1 CK20
Fig. 2. Metastatic adenocarcinoma from the colon. (A) Photomicrograph showing moderately differentiated tubular adenocarcinoma (H&E,
×100). (B) Immunohistochemical stain for CK20 shows membranous positivity (×100). (C) High magnification for CK20 immunoreactivity
(×400). (D) Immunohistochemical stain for TTF-1 shows negative reactivity (×100).
A B C DThus TTF-1 had a specificity of 0.95 (39/39+2) and a sen-
sitivity of 0.69 (20/20+9) for diagnosis of metastatic lung
carcinomas, whereas CK20 had a specificity of 1.00 (52/52+
0) and a sensitivity of 0.69 (11/11+5) for diagnosis of meta-
static GIT carcinomas.
DISCUSSION
In the surgical pathology practice, a relatively common
problem is to identify the primary site in the presence of a
lymph node metastasis. We frequently encounter patients
presenting initially with cervical lymphadenopathy. Accord-
ing to our experience, these patients with unknown primary
tumors were subjected to extensive, uncomfortable, and very
costly diagnostic procedures, including bronchoscopy, enteric
endoscopy, upper and lower gastrointestinal series, intravenous
pyelograms, angiography, mammography, and thyroid scan-
ning in an attempt to locate the primary tumor site.
Sometimes the anatomic location of a lymph node involved
by metastatic tumor provides an important indication of the
primary site of its origin. Notwithstanding the anatomic con-
nections between the location of neoplasms and their drain-
ing lymph nodes, metastatic tumors can be occasionally found
in unexpected and remote areas. Because of blockage of lym-
phatics by tumor cells with subsequent retrograde flow and
circulation shunts, paradoxical metastases, contralateral meta-
stases, and metastases of deep-seated tumors to peripheral
lymph nodes may be encountered (2). Therefore although
the most common sites of origin for each regional group of
lymph nodes are considered first, any other possible locations
of primary tumors must be systemically reviewed. 
Moreover, altered histopathological appearance of tumors
in metastatic sites can often make the diagnosis more diffi-
cult. Identifying the primary tumor is usually difficult, often
frustrating, yet indispensable to the treatment. All available
methods of histopathology, electron microscopy, histochem-
istry, and immunohistochemistry must be employed for this
important diagnostic process.
Various monoclonal antibodies have been developed with
high degrees of specificity, by which the detection and iden-
tification of numerous classes of molecules are feasible. The
monoclonal antibodies against specific markers for particu-
lar tissue or cell type can be used to identify their neoplastic
counterparts.
TTF-1, also known as thyroid-specific enhance-binding
protein or Nkx-2.1, is a member of the Nkx-2 gene family
of the homeodomain-containing transcription nuclear factors
that plays a pivotal role in tissue morphogenesis and cyto-
differentiation (5, 19, 20). TTF-1 gene expression is regu-
lated in respiratory epithelial cells at the transcriptional and
posttranscriptional levels by means of cross-regulatory mech-
anism, involving hepatocyte nuclear factor 3 (21), Oct-1 pro-
tein (22), GATA-6 (23), and calreticulin (24). TTF-1 is con-
sistently expressed in all pulmonary epithelial cells during
early embryogenesis. As the development proceeds, it is pro-
gressively downregulated in tracheal and bronchial columnar
epithelium, while remaining predominantly expressed in
type II pneumocytes and Clara cells (13). Current informa-
tion indicates that TTF-1 is almost exclusively expressed in
carcinomas of the thyroid and lung. Furthermore, the TTF-
1 expression in thyroid carcinomas is of only minor diagnos-
tic importance since thyroid carcinomas can be specifically
and sensitively identified by the immunohistochemical detec-
tion of thyroglobulin and thus discriminated from pulmonary
carcinomas. 
TTF-1 expression has been demonstrated in all types of
lung carcinomas. TTF-1 has been localized in 26% to 76%
of adenocarcinomas, in 0% to 38% of squamous cell carci-
nomas, in 40% of large cell carcinomas, in 0% to 50% of
typical carcinoids, in 40% to 75% of large cell neuroendocrine
carcinomas, and in 81% to 100% of small cell carcinomas
(14, 25, 26). In our study on metastatic lung tumors, TTF-
1 immunoreactivity was noted in 90.9% (10/11) of adeno-
carcinomas, in 37.5% (3/8) of squamous cell carcinomas,
and in 85.7% (6/7) of small cell carcinomas. The results of
our study performed on metastatic tumors of cervical lymph
nodes were similar to those from the previous reports of pri-
mary lung tumors (14, 25, 26). Interestingly, we found a
rather higher percentage of TTF-1 expression in metastatic
adenocarcinomas than in primary lung tumors. Puglisi et
al. (28) reported that non-small cell lung carcinomas with a
higher percentage of immunoreactive cells for TTF-1 showed
a poor prognosis. Pelosi et al. (27) reported that in adenocar-
cinomas, a stronger TTF-1 immunoreativity was generally
seen in tumors with increased microvessel diameter, size less
than 3 cm, and low proliferative fraction. They suggested
that TTF-1 may affect the growth of small adenocarcinomas,
which usually show low proliferative activity, via a mecha-
nism involving an increased number of vascular channels.
Our findings showed some discrepancy with the results of
Pelosi et al. (27). The cause for these differences may be ex-
plained by subtle technical differences among the studies and
diagnostic criteria for positive immunostaining. Further in-
vestigations are needed to determine the expression pattern
of differentiation markers of their cells of origin, in view of
the heterogeneous and variable nature of tumors during pro-
gression of metastasis. And it remains to be explained whether
the expression of TTF-1 protein is switched off or on during
tumor progression or represents local maturation in meta-
stasis. 
It is known that cytokeratin intermediate filaments have
twenty subtypes (17, 18). They are of different molecular
weights and show differential expression in various cell types
and tumors. Monoclonal antibodies to specific cytokeratin
subtypes have been used in an attempt to classify tumors ac-
cording to site of origin. Cytokeratin immunohistochemistry
has important applications in surgical pathology (17, 29). 
TTF-1 and CK20 Distinguish Metastatic Tumors 515CK20 is a major protein in mature enterocytes and goblet
cells of the intestinal villi. Although the biological function
of CK20 is unknown, the predominance of CK20-rich cells
in the luminal-exposed to regions of intestinal mucosa has
been proposed to confer a special mechanical stability (17, 18).
Gastrointestinal adenocarcinomas are frequently CK20-pos-
itive, whereas adenocarcinomas of the lung or female genital
tract (with the exception of mucinous adenocarcinoma of the
ovary) are almost always CK20-negative (17, 29, 30).
According to studies of CK20 immunohistochemistry in
lung cancer, CK20 immunoreactivity was low and observed
in 16.6% of metastatic non-small cell carcinomas of the lung
in the pleural fluid (31) and in 15% (5 of 33) of pulmonary
adenocarcinomas (18). In colon cancers, CK20 immunore-
activity was high and noted in 90 of 93 (97%) of adenocar-
cinomas of the colon (18) and shown to have a 100% sensi-
tivity in cytologic specimens of metastatic carcinomas (32).
In stomach cancers, CK20 immunoreactivity was noted in
50% of adenocarcinomas of the stomach (17) and in 68.7%
in cytologic specimen of metastatic carcinomas (31). The posi-
tive rates of CK20 immunoreactivity for metastatic gastric
cancer of our study and Ascoli et al. (31) were slightly high-
er than that of primary lesion in study of Moll et al. (17). It
also remained to be studied whether these differences are pro-
duced by the technical or interpretation differences or CK20
involves in tumor progression and metastasis.
In summary, the results of the present study indicate that
TTF-1 and CK20 should be the first choice as a component
of antibody panel to prove or to exclude the lung and GIT
origin, respectively, especially in patients presenting with
metastatic carcinomas of unknown primary site. Although
this method may not identify the primary tumor site in all
cases, it compares favorably with other special techniques in
this difficult diagnostic setting.
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